Dedicated to improving the current methods of treating cancer, DormaTarg, Inc. developed a revolutionary cancer model that identifies drugs
that can safely prevent cancer recurrence. Through this new model, senior cancer specialists and founders Dr. Robert Hurst and Dr. Michael Ihnat
have discovered three drugs that have shown to be non-toxic and highly effective in killing “dormant cancer cells,” the very cells responsible
for recurrence.
DormaTarg will continue to study the origin of cancer recurrence and give hope back to millions of cancer patients by helping
them successfully fight previously untreatable types of cancer.
Target Cancers
Several of DormaTarg's lead compounds have shown efficacy in the following types of cancer. Please click on the image to learn more about each type of cancer as well as the current status of our testing.
